this us, in RVTXXXX of week actually, last both from specifically data year an happened Thank a to to back. saying in talk well about we -- you, listening was everybody, you, together this study. as I team to But were our for quarters. amount slightly like be exciting anti-connected chronic talking period just the call it It's generally obviously It's the the recent really morning. feels Steph, enormous morning as and this thank has great for fiscal because
our ongoing providing our FcRn the results. of where A are a VTAMA well a out program, give great turn put year. line we'll updates through we're Q&A. refresh on the a and update, to on quick last the the as launch RGXXX, on those week on looking talk atopic financial of our quick do about of topics. then we as that data with update reminder updates little the We'll We'll to dermatitis some making course progress of we bit So over a We'll forward
Starting X. on Slide
March $XX of to as amount cash XX, cash are the especially which is incredibly which potential or And have sales Just progress of that we by made billion tremendous we'll study reported celebrated FDA supported successful. launch we've then by over data run most I&I an with half potential reminder XXth We runway to what XXXX first-in-class before that that believe second a III XX have we've a products dooring, run. level have in model. our X here. That's really the $X.X of continued this have share. industry-leading with we the of ongoing as late-stage kind studies a been now number our now consecutive setting, we've VTAMA or proud of We positive best of supports proud that quarter gotten programs. billion and we're We look, of in with the we of pipeline, a the of a of Phase recent approved out
year We've chronic year, Phase been in updates are we've look in we that said to the antibody all data dermatitis Slide support was our this III that XXXX exciting data that has next at provide pending the today, in to to induction for RVTXXXX, do to another We've we'll X patients that potential midway of along matter point, going of so class on think as studies our for our potential has ulcerative that really on shared now VTAMA be quarter and really, periods now an launch. great our top-end for right efficacy terms on We and ride which is that sharing. updates We've of is the supported option and think data. atopic we data DA we year. important both important study approval the really continue been forward new really HTTLXA program. both VTAMA, continued for of in phenomenal that and to will again data progress biggest of in colitis, to of both terms be will product and the an We've from
as anti-FcRn healthy well hope ongoing to finally, continued the will our anti-FcRn And in in Still believe we IMVT-XXXX, coming best-in-class that before that top-level volunteer of agent be, of potentially number in readout year, for number trials watched as studies as updates the bitoklimab and pivotal the patient closely the quarter this and more talk study of which we multiple indications. has class potential a antibody have or will comes, efficacy obviously fourth our establish franchise, and transformational show which efficacy we our brepocitinib we it a this of from including think program SLE, and that then again, population. XXX in TYKX/JAKX, a of it's in about to
Obviously, reminder, will in Slide just of those biggest and opportunities add on on last classes, our agents think we pipeline continue just coming a in the our we And of of with And like that X important we year. in overall pipeline X, proud some late-stage to bring I present of portfolio the we find more themselves. And within can to number certainly RVTXXXX. matter we immunology. really some just hope additions with are made as very to here months XX this as a IPTXXXX the
the an of launch section update start VTAMA. here So I commercial with the next on will in
excited evolve X, continues way for are that Slide VTAMA. say about I'll On demand to the very we
We in are best believe We topical. the launching novel psoriasis history.
have branded best shortly the been obviously in and our since are We very after psoriasis selling launch. topical
year We as really some in see build. our this has Slide of various and we progress grown, great it that early and we wanted demand continue just efforts expect On the including here make to the like way through the build coverage hit. things launch that continue XX, to end sure we to the DTC to
revenue did good in million in for March from we is product quarter. quarter, net which $XX.X a all, the XX million $X.X degree prior of First or $X pretty million up the
So a expected we the the progress that even happier we with year, since. made XX% sales we've frankly, in frankly, Maybe to obviously quarter this of to first number. during the happy with and of yield, faster coverage is quarter breadth that add from up net the XX%, than gross in which coverage reflection added, of the continued
forward net improvements happy we that. to to earlier I really year. trajectory ways, we're to year, feel over more and think the this some with talk In So about pull time. about continue that We'll our we good managed gross through
on margin expectation we're we launched major formularies covered the of addition now perspective, coverage a of than within and period. during This From XX at of the launch. year national by XX, this up XX% time PBM formulary health regional a product. commercial well includes An our national better -- with PV plan the to a meaningful X important This Slide ABS X formularies, X plans. lives is
of which when to population the the as So product just which that coverage. be that matters us And through and gives to launched we is a where really steroids, patient is the us. coverage step majority we most significant reminder, access single wanted great exactly to
XXX,XXX psoriasis almost atopic X,XXX more week a are there reminder, currently And doing topical dermatitis. scripts and little than corticosteroid or week. we're a scripts bit X,XXX between every about As a
in that we're So both excited well. opportunity, of that psoriasis room in today FDA as approval a and we have to really a ton to do pending into and grow dermatitis
XX on we together talk put in reminder which data. Dorint it's well, a extremely as out dermatitis, atopic Speaking great a lot the on the data This here, little about the to DRX March, we've -- just consistent. is talked of Slide is We just this call got data about data.
terrific data It's rates, really this. IGA reported in here. was very is response about EXX. that of good on quality it's excited The the really data idea are happy I'm really we really And with really, itch, patients. the disease -- We that going data NAD, in a about well a adults very by And market as good to equivalent. like for these difference big looked which children feel really is and make are
of of little low bit a think agent frankly, very rates dermatitis low better safety. And with that our very agent all clear psoriasis of and really in patients with HX, tolerability botulin and pediatric this is than the atopic in reminder, way is in from rates especially events. is we good, which patients right a the that in this And went pediatric the patient unmet pediatric you all the XX. large Slide patients there significant. need thing a is saw as very dermatitis, down maybe to even follicular because I Across very, data on contact care it's study topical is One about
the will that we profile patients. exactly a of matter profile clean a Just gives product and to us physicians think
data the perspective about safety excited really from So as a well.
I spend dermatitis. is in else in much or in better with atopic and too XX, even comparison severe number is crush the moderate time on same ballpark of systemic hot data on looks anything a competitive the this population Slide agents patient better topical but that than that won't to or a certainly
the So more the updates Dermavant share year. on course of to over
Looking in franchise. cover, to progress continue forward to looking forward the
year. the providing filing D, be next which of we forward for very expect SNDA Vitamin updates at Looking on the calendar to to beginning
sharing to quarters to forward in come. Looking those
give and brief reminder. out now is So just I'm to This that put a week. we going pivot data last
very own, point time won't of with earlier of XX-week showed go-forward in the it's improvements incredible with This On class and basically that its our this dose. this and between we year. great data endpoints RVTXXXX. remarkable the program reported Slide between our be data. right? XX that this a last across I of of program to a on also XX, lot efficacy, substantial So real drugs all is a antibodies and competitors data we Anti-T at are We is of sort shown one to spend proper-blinded X believe our show it of week and in class has first week. really agent proud And
data, anti-TLXA talked population that meaningful about UC point patients of in to only is long-term antibody the over set relative of the this valid efficacy all-comers we efficacy with a relevant are have XX% the improvement We we've data. biomarker that we XXX to at bit and population. have with a
in ground that agent seen very we've get has trial. to the the people impact the program, for study then was a And been are run And on to we know no this safety far. of which in so immunogenicity hoping good question
updates III is now with coming in and with full we'll the just this future, Phase with a single program discussion near that we're which run to provide FDA, So a simple a summer. speed after plan ahead on subcutaneous here dose our
of remission. Maoclinical [indiscernible] This Phase we As a an in all-comers what with is reminder we agents XX a X. XX% this endostatic on of to It's go population we were of this weeks don't XX% our III remarkable Phase the reported. XX% the there XX% data, Slide frankly, something so KNR excited was remission, from I'll dose, it typically And modified patients see go saw the and of with achieving XX in then quickly weeks, a We very endostatic that, endoscopy. really and dose, And hit, on improvement. week XX. XX few on III to clear in at saw
again, patients. are XX, Once exciting by dose suggesting the gets it remission markers disease-modifying Phase having I at patients to here. biomarker the which a measure remission potential we really endostatic in XX% impact But endostatic improvements. at data antifibrotic III that XX% we better look week didn't specific of up Slide personally, data look, that you even week these XX, clinical overlay patients are And on XX% this the meeting XX, on no a of looks in
So really exciting.
hard a and XX% here is biomarker, with population but are weeks, reminder, -- just includes which really endostatic improvement. shown study in a chosen whole data doses patients This some our of XX this best biologic saw, recalcitrant frankly, other that been in XX% a data treat. large reminder, and patients who the remission the are that's as optimally And we data topic we also Another shared, phenomenal to experience, at in as biologic patients, dose. bilas-experienced clinical on of than patient generally our for patients, this is experience just
even in III large great when numbers. end for expect studies our we So improvement that really Phase room generate data there's over these we
to later And reach population. very way in about So feel potential our I where experience the efficacy be excited we biologic for very in that data going lines look at agent great any a sufficient that judgment, is think a the of confident and there's this we to therapy.
safety up profile. the Obviously, in because really mechanism is has Slide things anti-inflammatory one a class, get see other to our exciting a of tissue the it that things you on safety other of that by of can be and sort really some only way TLXA the and in works disease TLXA amplifier terms about all backed is good because And XX you you of the signal of inflict in don't present classes. infection see data
had And X% no and infections so chronic to rate infections severe greater no in observed we the observed period. equal
And just all the to to really we practice saw were determined drugs. good doses generally, well AEs by XXX, sponsor at and profile a serious be safety not tolerated related
questions XX Slide the the I a mean going we going into the whether think clean the to We we were forward. profile safety a drug was maintenance one going going So that period utility is reminder, very not. then the matter. was finally, that of on lot confident on is of data reasonably that got And as help it was to
Patients a have see than effect, We be patients ADAs don't can data had rate better in all the real having arms expected And pool X we the say III the We you at just noise. this ADAs, this and We is no rising to week across across of flat across remission study. was or with arms on by that uncorrelated of with X antibody ADA quartile impact safety this slide it expect What large, without is in the is efficacy and the ADAs middle, of titer. perhaps down. our obviously. on clinical dose. are and think I the XX, this somewhat to the we was all the the study. think it think said Phase chart
that no So we XX are. mutualizing antibodies patients that on have
feel it is here. of the field really without to the quite XX, about we differentiated too relative Slide great belaboring we point that On much, data amount here, and have the
have including over year how hundreds dosed you it. dosing, seasons across XXX X patients of XXX cut no basis IV subcutaneous patients subjects dose and We XXX dosed, of a to across dosed doses, X an just matter out
anything with subcutaneous data, long-term the quantum with only here We are agent only the agent this like data. here of
once-monthly form Our prospectively which a tested patients, that is specified subcutaneous in obviously auto-injector. biomarker, has expect factor been commercial many and a we
show class, other about which the really we we where So of the data given great versus target. feel promising our profile also have agents in quality will expect this the
initiated, to II study disease. study. Finally, I ranging to The I straightforward, Phase on that we the could study optimal we like Crohn's, Slide XX, a the wanted a run in ground without is is to similar Phase highlight, sense possibly in week, single-dose first-in-class study XXX basic patients mentioned quickly just in that Crohn's to monthly for we study we doing just that we ran to run Phase the want will would done doses subcutaneous in that that patients. question as a on ranging see in It's over any proper us quickly back took placebo in arm get we period, we giving III felt have dose be as XX allow and Crohn's It with the a was will get as that up IIb X endpoints, to see by study we'll could. we There as just realized, last patients. One opportunity expect you UC. This again, we similar study dose step set that similar a we XX-week weeks as is start dosing and are simple chronic a you of be of be answer which can in very followed because to Slide a wanted XX. we on
study And wanted make in attractive for to so to we enroll really this starting patients now. a
And so up running. study have trying to that we're and
program. really excited about So overall, XX Slide XX, just as a reminder or Slide this sorry, on --
to think anchor an improvements we to We forward will highest later-line think among clinical reported. efficient path ever We including our will the be are uniquely first-in-class anti-TLXA dose remission limitations with therapy sustained it I antibody in carried therapies, the late-stage a in III. it single some of is a pipeline. efficacy on with endoscopic well validated of IVD think the major Phase positioned overcome and we
high supports further think and therapy. for a clinical options differentiates an finally, will an for targeting expectation well class just of although population the our fibrotic opening well is for notably, on markets and we and be patient biomarker the opportunity data this underway just up gives indications clearly inflammatory even I as additional our of remission We many of we're both higher other that as large that, agent our look status line more approval. with that rate, in us growth, range treatment all-comers we of IBD And our as that biomarker soon study sharing a with beyond and patients then an additional D, Crohn select that as to that we'll forward patients versus mentioned dual the Diab population, targeting end opportunities for including or study pathways, go And need think studies. is a to irrespective
And franchise. minutes we was has what everybody about program. just to a new section, IMG-XXXX wanted Finally, there's excited in spoken anti-FcRn the no our few on given of and remind spend are this Obviously, I want updates coming, to Immunovant but program. this how about
in years with proper and pivotal couple first-generation data as in reminder, MDD as coming with XX, well franchise antibodies next studies over a a as batoclimab Slide others. currently the those multiple of we CIDP across have on studies So in our antisera
have showing will batoclimab, IgG minimal and for the useful being albumin in an best-in-class chronic have antibody, believe LDL diseases interaction And impact then as next we with our and while population. even same on INT-XXXX, larger suppression dosing which of therefore, we
for dose program the is We data that agent establish to in have sending data. October November And potential think class. we multiple from September that in dose August, has sending data that best single coming in for
we both of the the home market, simple these any subcu-programs will at something agents of not sort are classic also point, with something of which reminder, a agents comparable other They administered. on in this be proper we the of straightforward today. and do have think As differentiated and They other we subcus. subcu-injections. administered, is They believe at class sort are subcutaneously very are believe,
Our I as and multiple single data Phase we as believe IMVT-XXXX we we is that study underway, are dose ongoing I study that ascending year, and we I And mentioned. hand That the NHP we've that have that's have likely -- data this later in has, that cohorts. said, to looking sharing forward is shared ascending IGG, data, these batoclimab, for a based questions other on calls be both think on data. on MAD predictive success. we on putting a out number of albumin we and on war fair data forums. of the usefully of the I will be data our the may the at summer and for And get SAD which end
be I and clean but on And of we albumin variability. the this engineered we the be programs bit have one that although on and LDL. little believe clear, NHP and guess has is, seen data based data none the the albumin that, about way the say And assay look, a should than these to like has LDL today. XX% that specific in I'd frankly, Remember thing assay more is some based a are to variability we
this information expectation will days NHP no the have but show to I what about and from So ought clean. be our
surge be that in even us a meaningful. tell would up for advisers to, of clinically example, LDL not Our XX%
through was the as and there should team forward that that with optimistic later sharing data, NHP we the to well that together good data way to forward looking getting it. a have given So year this the engineered as drug to result look go that Immunovant
update and XX, for Finally, Slide the a open Q&A. brief financial on I'll then give line we'll
million XX. net revenue $XX quarter the about $XX net of the net showed net we product for So revenue product ending of revenue and including March of for And revenue of million million about fiscal or $XX million, year. $XX
million. For million expense R&D the SG&A R&D quarter, was adjusted or million. had expense $XXX about we of or adjusted $XXX $XXX about And $XXX million
and So consistent prior quarters perspective. spend with a burn from
feel into with And we notably, billion us year guidance second $X.X giving carrying over as opportunity in lots equivalents, about half us far good of to of cards. the ended fiscal we as that turn cash XXXX which data
all come frankly. I'll through in to of go on of of won't very long important we've some programs is them say but I including just Slide about here, a developments, look, talked there about list catalysts the So we've talked little XX.
team listening together. thank line And to sharing all for filed. patients a the those is pause second that our It's of believe the this you, so we to us. looking to on getting will want call It's for at this back Roivant and look data turn as to year over and with tremendous to I well everybody. Thank I And forward XX-K we're forward been only that, hard Q&A. the fiscal as us. being with
